Disc Medicine Inc IRON

$56.84 +0.19 (0.34%)

Valuation

Market cap
217,958,000
Revenue TTM
$0
Net income TTM
$-212,180,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.09

Trading

Volume
569,500
Avg volume
535,882
Day's range
$55.00 – $57.24
Shares out
3,835,000
Stochastic %K
19%
Beta
0.93
Analysts
Strong Sell
Price target
$103.17

Price

Company profile

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formati...

Show more

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 674 9274
Website
https://www.discmedicine.com
Address
321 Arsenal Street, Suite 101, Watertown, United States

Latest news

Stocktwits

Merlintrader Oct 9, 11:25 PM
Disc Medicine $IRON: Bitopertin and APOLLO APOLLO data are guided for Q4. After the FDA complete response letter, the central question is clinical benefit, not just lower protoporphyrin. https://www.merlintrader.com/disc-medicine-stock-hub/
0 replies
Loosewin Oct 8, 1:37 PM
Sold $IRON Nov20'26 40 PUT for 3.3 per contract.
0 replies
BullishBellee Oct 4, 6:09 PM
$IRON Strong Phase 2 data in myelofibrosis-associated anemia..::
0 replies
Night_Owl_Biotech Sep 26, 1:43 AM
$STOK is off 26% over the last 4 weeks. As near as we can tell, the evidence suggests STOK's Zorevunersen is as likely to be approved for Dravet as any peer submission targeting any non-oncology disease/condition. The graph compares STOK analyst consensus revenue estimates v $IRON which, as we understand it, also anticipates approval in the near-term. More important, analysts project both to generate roughly the same revenues over the next 9 years. Analysts project STOK to outsell IRON by roughly 10% yet STOK now trades at a meaningfully lower valuation. Revenue multiples are provided. More than 10 analysts cover both & at least 6 for each provide projections through FY35. We're unaware of either's anticipated gross manufacturing margins. If anyone can provide any insight it would genuinely be appreciated. This is not investment advice. $XBI $IBB
1 replies
Trainguy1 Sep 18, 1:13 PM
$IRON Disc Medicine expects to have a lot of news and information to share in Q4: - Bitopertin (Erythropoietic Porphyrias - EPP/XLP): Topline data from the fully enrolled Phase 3 APOLLO Trial are expected in Q4 2026, which will serve as the basis to support traditional approval. - DISC-0974 / Selcodibar (Myelofibrosis Anemia): Topline Phase 2 RALLY-MF data updates and an End-of-Phase 2 meeting with the FDA are anticipated in H2 2026 / Q4 2026. - DISC-3405 (Polycythemia Vera & Sickle Cell Disease): Initial clinical data from the Phase 2 study in polycythemia vera and the Phase 1b study in sickle cell disease are expected in Q4 2026.
0 replies
peloswing Sep 16, 4:43 PM
UOA: $510K+ of the $IRON $75 Call for 10/16 🐳
0 replies
peloswing Sep 14, 6:39 PM
$IRON $75 calls for Nov. 20th - $468,000+ net buying The stock has a $102.58 average price target: 48.46% higher 🟢
1 replies
justiceforb_85 Sep 14, 2:48 AM
$IRON main catalyst for Q4 is bitopertin P3 data. We'll see if lowering PPIX levels results in a clinically meaningful change in sunlight tolerance. Lean positive.
0 replies